CU22921A1 - Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales - Google Patents
Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectalesInfo
- Publication number
- CU22921A1 CU22921A1 CU1999196A CU1999196A CU22921A1 CU 22921 A1 CU22921 A1 CU 22921A1 CU 1999196 A CU1999196 A CU 1999196A CU 1999196 A CU1999196 A CU 1999196A CU 22921 A1 CU22921 A1 CU 22921A1
- Authority
- CU
- Cuba
- Prior art keywords
- murine
- antibody
- ior
- diagnosis
- recombinant antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La presente invención se relaciona con la obtención de nuevos anticuerpos recombinantes a partir del anticuerpo murino ior C5 producido por el hibridoma depositado según el tratado de Budapest bajo el número ECCC 97061101. dichos anticuerpos recombinantes se obtuvieron mediante el empleo de la tecnología del ADN recombinante, y están caracterizados por su reconocimiento al antígeno denominado ior C2. los anticuerpos recombinantes son específicamente, el anticuerpo quimérico, el anticuerpo humanizado y el fragmento tipo Fv de cadena sencilla. El anticuerpo quimérico contiene los dominios variables de la inmunoglobulina murina y las regiones constante de la inmunoglobulina humana. El anticuerpo humanizado, contiene las regiones constante de la inmunoglobulina humana y ha sido modificado específicamente en la región de los marcos (FRs) murinos y dentro de estos en aquellas zonas que pudieran resultar en un sitio antigénico para las células T. El fragmento Fv contiene los dominios variables de la inmunoglobulina murina. La presente invención además se relaciona con el uso de los anticuerpos recombinantes derivados del anticuerpo murino ior C5 para el diagnóstico y terapia de tumores colorrectales, sus metástasis y recidivas. Para ello la presente invención proporciona una composición que contiene anticuerpos monoclonales reducidos que reconocen el antígeno ior C2 y un ligando débil, el MDP con el agente reductor Sn2+ para realizar el radiomarcaje del anticuerpo con Tc-99m, Re-186, R-188 y sus similares, útil para el diagnóstico por inmunogammagrafía y radioinmunoterapia de tumores colorrectales, metástasis y recidivas.
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU1999196A CU22921A1 (es) | 1999-11-16 | 1999-11-16 | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales |
ARP000105994A AR026463A1 (es) | 1999-11-16 | 2000-11-14 | ANTICUERPOS Y FRAGMENTOS Fv QUE RECONOCEN EL ANTIGENO ior C2 |
CO00087150A CO5280154A1 (es) | 1999-11-16 | 2000-11-16 | Anticuerpos y fragmento fv que reconocen el antigeno ior c2 |
PCT/CU2000/000004 WO2001036485A2 (es) | 1999-11-16 | 2000-11-16 | Anticuerpo monocolonal recombinante que reconoce el antigeno ior c2 su uso para el diagnostico y tratamiento de tumores colorectales |
CA002359577A CA2359577A1 (en) | 1999-11-16 | 2000-11-16 | Antibodies and fv fragment recognizing antigen ior c2 |
US09/889,480 US6891023B1 (en) | 1999-11-16 | 2000-11-16 | Antibodies and Fv fragment recognizing antigen IOR C2 |
CNB008039542A CN1230446C (zh) | 1999-11-16 | 2000-11-16 | 识别抗原ior c2的抗体和fv片段 |
KR1020017008965A KR100827627B1 (ko) | 1999-11-16 | 2000-11-16 | 항원 아이오알 시2를 인식하는 항체 및 에프브이 단편 |
JP2001538974A JP2003514831A (ja) | 1999-11-16 | 2000-11-16 | 抗原IORC2を認識する抗体およびFvフラグメント |
EA200100782A EA005169B1 (ru) | 1999-11-16 | 2000-11-16 | РЕКОМБИНАНТНОЕ АНТИТЕЛО, ВЗАИМОДЕЙСТВУЮЩЕЕ С АНТИГЕННЫМ КОМПЛЕКСОМ IOR C2, Fv- ФРАГМЕНТ УКАЗАННОГО АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
MXPA01007261A MXPA01007261A (es) | 1999-11-16 | 2000-11-16 | Anticuerpos y fragmentos fv que reconocen el antigeno ior c2. |
BR0007827-1A BR0007827A (pt) | 1999-11-16 | 2000-11-16 | Anticorpos e fragmento fv que reconhecemantìgeno ior c2 |
EP00977398A EP1174441A2 (en) | 1999-11-16 | 2000-11-16 | Antibodies and fv fragment recognizing antigen ior c2 |
AU15130/01A AU783622B2 (en) | 1999-11-16 | 2000-11-16 | Antibodies and FV fragment recognizing antigen IOR C2 |
TW089126622A TWI233440B (en) | 1999-11-16 | 2001-01-30 | Antibodies and FV fragment that recognise IOR C2 antigen |
ZA200105803A ZA200105803B (en) | 1999-11-16 | 2001-07-13 | Antibodies and FV fragment recognizing antigen IOR C2. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU1999196A CU22921A1 (es) | 1999-11-16 | 1999-11-16 | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales |
Publications (1)
Publication Number | Publication Date |
---|---|
CU22921A1 true CU22921A1 (es) | 2004-02-20 |
Family
ID=5459527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU1999196A CU22921A1 (es) | 1999-11-16 | 1999-11-16 | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales |
Country Status (16)
Country | Link |
---|---|
US (1) | US6891023B1 (es) |
EP (1) | EP1174441A2 (es) |
JP (1) | JP2003514831A (es) |
KR (1) | KR100827627B1 (es) |
CN (1) | CN1230446C (es) |
AR (1) | AR026463A1 (es) |
AU (1) | AU783622B2 (es) |
BR (1) | BR0007827A (es) |
CA (1) | CA2359577A1 (es) |
CO (1) | CO5280154A1 (es) |
CU (1) | CU22921A1 (es) |
EA (1) | EA005169B1 (es) |
MX (1) | MXPA01007261A (es) |
TW (1) | TWI233440B (es) |
WO (1) | WO2001036485A2 (es) |
ZA (1) | ZA200105803B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
CA2643100A1 (en) * | 2006-02-28 | 2007-09-07 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
CN103492852B (zh) * | 2011-04-28 | 2016-08-17 | 独立行政法人理化学研究所 | 生物材料的透明化方法、及其利用 |
US10444124B2 (en) | 2011-05-20 | 2019-10-15 | Riken | Clarifying reagent for biological materials and use thereof |
EP3035026A4 (en) | 2013-08-14 | 2017-04-26 | Riken | Composition for preparing biomaterial with excellent light-transmitting property, and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
DE69704702T2 (de) | 1996-03-07 | 2001-11-29 | Agfa Gevaert Nv | Gerät zur entwicklung von photographischem blattmaterial |
CU22640A1 (es) * | 1996-03-12 | 2000-12-22 | Centro Inmunologia Molecular | Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas |
-
1999
- 1999-11-16 CU CU1999196A patent/CU22921A1/es unknown
-
2000
- 2000-11-14 AR ARP000105994A patent/AR026463A1/es active IP Right Grant
- 2000-11-16 KR KR1020017008965A patent/KR100827627B1/ko not_active IP Right Cessation
- 2000-11-16 WO PCT/CU2000/000004 patent/WO2001036485A2/es active Application Filing
- 2000-11-16 EP EP00977398A patent/EP1174441A2/en not_active Ceased
- 2000-11-16 AU AU15130/01A patent/AU783622B2/en not_active Ceased
- 2000-11-16 CN CNB008039542A patent/CN1230446C/zh not_active Expired - Fee Related
- 2000-11-16 CO CO00087150A patent/CO5280154A1/es active IP Right Grant
- 2000-11-16 US US09/889,480 patent/US6891023B1/en not_active Expired - Fee Related
- 2000-11-16 JP JP2001538974A patent/JP2003514831A/ja active Pending
- 2000-11-16 CA CA002359577A patent/CA2359577A1/en not_active Abandoned
- 2000-11-16 BR BR0007827-1A patent/BR0007827A/pt not_active Application Discontinuation
- 2000-11-16 MX MXPA01007261A patent/MXPA01007261A/es active IP Right Grant
- 2000-11-16 EA EA200100782A patent/EA005169B1/ru not_active IP Right Cessation
-
2001
- 2001-01-30 TW TW089126622A patent/TWI233440B/zh not_active IP Right Cessation
- 2001-07-13 ZA ZA200105803A patent/ZA200105803B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1344276A (zh) | 2002-04-10 |
CO5280154A1 (es) | 2003-05-30 |
AU783622B2 (en) | 2005-11-17 |
WO2001036485A2 (es) | 2001-05-25 |
KR100827627B1 (ko) | 2008-05-07 |
ZA200105803B (en) | 2003-01-06 |
JP2003514831A (ja) | 2003-04-22 |
US6891023B1 (en) | 2005-05-10 |
WO2001036485A3 (es) | 2001-11-08 |
BR0007827A (pt) | 2001-10-30 |
MXPA01007261A (es) | 2002-06-04 |
CN1230446C (zh) | 2005-12-07 |
KR20020008113A (ko) | 2002-01-29 |
AR026463A1 (es) | 2003-02-12 |
CA2359577A1 (en) | 2001-05-25 |
EA200100782A1 (ru) | 2002-02-28 |
TWI233440B (en) | 2005-06-01 |
EA005169B1 (ru) | 2004-12-30 |
EP1174441A2 (en) | 2002-01-23 |
AU1513001A (en) | 2001-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schultes et al. | Anti-idiotype induction therapy: Anti-CA125 antibodies (Ab 3) mediated tumor killing in patients treated with Ovarex mAb B43. 13 (Ab 1) | |
EA200301098A1 (ru) | Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей | |
Jan Fagerberg et al. | Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A | |
DE69529649D1 (de) | Anti-egfr einkettige fvs und anti-egfr antikoerper | |
PE20050422A1 (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 | |
NO933179L (no) | Anti-idiotype antistoffer overfor human melanoma-assosiert proteoglykanantigen | |
MX9201016A (es) | Anticuerpos monoclonales humanizados y quimericos | |
FI963033A (fi) | Tuumorirejektioantigeenin esiasteeseen MAGE-1 sitoutuvia monoklonaalisia vasta-aineita, rekombinantti-MAGE-1 ja MAGE-1-peräisiä immunogeenisia peptidejä | |
CU22921A1 (es) | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales | |
US6794494B1 (en) | Cancerous disease modifying antibodies | |
PT90582A (pt) | Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen | |
US20050027106A1 (en) | Cancerous disease modifying antibodies | |
Kusama et al. | Syngeneic antiidiotypic antisera to murine antihuman high-molecular-weight melanoma-associated antigen monoclonal antibodies | |
Irvine et al. | Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72 | |
US20040141914A1 (en) | Cancerous disease modifying antibodies | |
Saito et al. | Establishment of internal-image anti-idiotype monoclonal antibodies to a human antibody to lung cancer | |
ABE et al. | Novel immunization protocol and ELISA screening methods used to obtain and characterize monoclonal antibodies specific for human light chain variable-region subgroups | |
DE69024758D1 (de) | Neuartige antiidiotypische monoklonale Antikörper | |
CY1107163T1 (el) | Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων | |
CN117624353A (zh) | 结合平滑肌肌球蛋白重链的抗体及其用途 | |
REINSBERG et al. | Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43. 13? | |
AU2007222842A1 (en) | Cancerous disease modifying antibodies for diagnostic and therapeutic use in breast and prostate cancer | |
AU2006346988A1 (en) | Cancerous disease modifying antibodies | |
Koprowski | Monoclonal antibodies in the study of human cancer | |
TH54150B (th) | แอนดิบอดี และชิ้นส่วน FV ที่รู้จัก ior C2 แอนดิเจน |